Prescription Drugs: Development, Pricing and Abuse

Rebecca McCay (Editor)

Series: Health Care in Transition
BISAC: HEA028000

Clear

$160.00

Volume 10

Issue 1

Volume 2

Volume 3

Special issue: Resilience in breaking the cycle of children’s environmental health disparities
Edited by I Leslie Rubin, Robert J Geller, Abby Mutic, Benjamin A Gitterman, Nathan Mutic, Wayne Garfinkel, Claire D Coles, Kurt Martinuzzi, and Joav Merrick

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Details

The Food and Drug Administration (FDA) awards priority review vouchers (PRV) to drug sponsors that develop drugs for tropical diseases or rare pediatric diseases or to use as medical countermeasures. The PRV—which can be sold to another drug sponsor—may be redeemed later to receive priority review from FDA with a targeted review time of 6 months, rather than the 10-month standard review, for a drug application of the PRV holder’s choice. Chapter 1 examined the number of PRVs awarded and redeemed and the drugs for which they were awarded or redeemed, and what is known about the extent to which the PRVs provide incentives for developing drugs to meet unmet needs.
Chapter 2 examines the prevalence of obesity in the United States, and what is known about the use and health insurance coverage of obesity drugs. Chapter 3 discusses how to get medical care and prescription drugs during a disaster or when an emergency has been declared.
The 340B Drug Pricing Program was created in 1992 to enable eligible covered entities—including certain categories of hospitals—to obtain discounts on covered outpatient drugs. Chapters 4-6 examine various aspects of this Medicare program.
Chapter 7 provides an overview of how drug prices are established under Part D and describes elements of various proposals for Secretarial negotiation.
To mitigate the effects of the opioid crisis in Philadelphia, a nonprofit called Safehouse announced plans to open a supervised injection site where illicit drug users could consume opioids under the supervision of trained staff, receive medical intervention in case of an overdose, and access services including addiction treatment. Chapter 8 discusses the Safehouse litigation’s importance for Congress by first providing relevant factual and legal background, before identifying select considerations for Congress related to the treatment of supervised injection sites under the CSA.
Parents are often concerned that their children will start (or are already) using drugs such as tobacco, alcohol, marijuana, and others—including the misuse of prescription drugs. Research supported by the National Institute on Drug Abuse (NIDA) shows the important role that parents play in preventing drug use in their children.Chapter 9 highlights parenting skills that are important in preventing the initiation and progression of drug use among youth.
(Imprint: SNOVA)

Preface

Chapter 1. Drug Development: FDA's Priority Review Voucher Programs (43)

Chapter 2. Obesity Drugs: Few Adults Used Prescription Drugs for Weight Loss and Insurance Coverage Varied (71)

Chapter 3. Getting Medical Care & Prescription Drugs in a Disaster or Emergency Area (8)
Department of Health and Human Services

Chapter 4. Drug Discount Program: Improvements Needed in Federal Oversight of Compliance at 340B Contract Pharmacies (14)

Chapter 5. Drug Discount Program: Status of Agency Efforts to Improve 340B Program Oversight (19)

Chapter 6. Drug Discount Program: Characteristics of Hospitals Participating and Not Participating in the 340B Program (32)

Chapter 7. Negotiation of Drug Prices in Medicare Part D (3)
Suzanne M. Kirchhoff

Chapter 8. Reducing Harm or Enabling Substance Abuse? Supervised Injection Sites Under Federal Drug Law
Joanna R. Lampe

Chapter 9. Family Checkup: Positive Parenting Prevents Drug Abuse
National Institute on Drig Abuse

Index

You have not viewed any product yet.


SHOW ALL OF MY RECENTLY VIEWED BOOKS